Return to CBI Antibody Core Home Page
  Return to human list
    Return to human ( Homo sapiens ) list


human ( Homo sapiens )
PIP5KIgamma


Links to multiple antibodies on this page for PIP5KIgamma:
PIP5KIgamma
PIP5KIgamma


Western result: +
control
PIP5KIgamma
A1155b
(fragment)

33.08 kDa (recombinant)
The western blot contains a test lane of ~20ug of a total protein extract from E coli with ~50ng to 500ng of the antigen (recombinant fusion protein containing a His tag). The negative control lane is the same except it contains ~50ng to 100 ng of a recombinant fusion protein of an irrelevant antigen. The blot was probed with a final antisera dilution of 1:1,000. The secondary antibody (Rabbit anti-mouse IgG + IgM, (H+L) horseradish peroxidase conjugated (Pierce)) is used at 1:5,000 dilution. Note, the molecular weight of the band on the western blot does not correspond to the molecular weight of the natural protein because only a fragment of the gene is used.

Antibody Name/Abbreviation: PIP5KIgamma
CBI Antibody Core Code: A1155b

"Lot" Number: 1 Position: 28 (641-668)
% Identical Homology of Target to Mouse Protein: 89% (NP_032870.1| phosphatidylinositol-4-phosphate 5-kinase, type 1 gamma)
Molecular Weight of GST-fusion: 33.08 KDa

Target sequence used to make this antibody:
PTDERSWVYSPLHYSAQAPPASDGESDT






Antibody Name/Abbreviation: PIP5KIgamma
CBI Antibody Core Code: A1155a

"Lot" Number: 1 Position: 20 (549-568)
% Identical Homology of Target to Mouse Protein: 95% (NP_032870.1| phosphatidylinositol-4-phosphate 5-kinase, type 1 gamma)
Molecular Weight of fusion protein: 32.2 KDa

Target sequence used to make this antibody:
YRRRTQSSGQDGRPQEEPPA






Sequence Name: PIP5KIgamma
Full name: phosphatidylinositol 4 phosphate 5 kinase I gamma
UniGene Number: N.A.
Accession Number: NP036530
Source organism: human ( Homo sapiens )
Full length size (aa): 668
NCBI information page:

Full length sequence:
melevpdeaesaeagavpseaawaaesgaaaglaqkkaaptevlsmtaqp
gpghgkklghrgvdasgettykkttsstlkgaiqlgigytvghlsskper
dvlmqdfyvvesiffpsegsnltpahhfqdfrfktyapvafryfrelfgi
rpddylyslcneplielsnpgasgslfyvtsddefiiktvmhkeaeflqk
llpgyymnlnqnprtllpkfyglycvqsggknirvvvmnnilprvvkmhl
kfdlkgstykrraskkekeksfptykdldfmqdmpegllldadtfsalvk
tlqrdclvlesfkimdyslllgvhnidqhererqaqgaqstsdekrpvgq
kalystamesiqggaargeaiesddtmggipavngrgerlllhigiidil
qsyrfikklehtwkalvhdgdtvsvhrpsfyaerffkfmsntvfrknssl
ksspskkgrggallavkplgptaafsasqipsereeaqydlrgarsyptl
edegrpdllpctppsfeeattasiattlsstslsiperspsetseqpryr
rrtqssgqdgrpqeeppaeedlqqitvqvepacsveivvpkeedagveas
pagasaavevetasqasdeegapasqasdeedapatdiyfptderswvys
plhysaqappasdgesdt





Questions? Click here for answers.


© Monday, February 16, 2009 by the CBI Antibody Core and the Center for Biomedical Inventions, University of Texas Southwestern Medical School.